Venclexta + azacitidine receive breakthrough therapy designation from FDA for myelodysplastic syndromes

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Venclexta (venetoclax) in combination with azacitidine was granted Breakthrough Therapy Designation from FDA for the treatment of adult patients with previously untreated intermediate, high- and very high-risk myelodysplastic syndromes based on the revised International Prognostic Scoring System. 

This designation was granted based on interim results from the phase Ib M15-531 study investigating Venclexta plus azacitidine in people with previously untreated, higher-risk MDS.

This is the 38th BTD for Genentech’s portfolio of medicines, and the 11th designation for its hematology portfolio.

Venclexta is being developed by AbbVie and Genentech, a member of the Roche Group.

Table of Contents

YOU MAY BE INTERESTED IN

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login